RETRACTED: Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development
Open accessAbstract
This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the editors. This article was published on October 19, 2010, and Figures 4A and 7A were later corrected on August 8, 2016. In January 2021, The Ohio State University notified the Cancer Cell editors that an internal investigation concluded that Figures 1E, 4A, 4D, 5A, and 7A were falsified and that part of Figure 1E of the article is the same as part of Figure 1F in the correction of another article (Pichiorri et al., 2017, J. Exp. Med., 214, 1557, https://doi.org/10.1084/jem.2012095001172017c) and recommended retraction of the article. The editors no longer have confidence in the validity of the data and are retracting the article. S.-S. S. agrees with the retraction, and F.P., C.H., A.P., and C.M.C. disagree with the retraction; all other authors couldn't be reached or didn't respond.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In multiple myelomas with wild-type p53, p53 can induce mir-192, mir-194 and mir-215, which subsequently downregulate MDM2 expression.
“Although perhaps expected in normal cells, it was surprising to find that in multiple myelomas in which p53 is wild type, p53 can induce the expression of mir-192, mir-194 and mir-215, which subsequently downregulate MDM2 expression50.”
From MDM2, MDMX and p53 in oncogenesis and cancer therapy (2013) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
2 retracted
Garofalo, M., Leva, G. D., Romano, G., Nuovo, G. J., Suh, S., Ngankeu, A., Taccioli, C., Pichiorri, F., Alder, H., Secchiero, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.014 · Cited by 731 · see citing works
Self-citationRetractedTai, Y., Podar, K., Catley, L. P., Tseng, Y., Akiyama, M., Shringarpure, R., Burger, R., Hideshima, T., Chauhan, D., Mitsiades, N., et al. (2003) · PubMed · Cited by 189 · see citing works
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714 · see citing works
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · see citing works
Prediction of Mammalian MicroRNA Targets
Lewis, B. P., Shih, I.-H., Jones-Rhoades, M. W., Bartel, D. P., & Burge, C. B. (2003) · Cell · doi:10.1016/s0092-8674(03)01018-3 · Cited by 4,333 · see citing works
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works
Miranda, K. C., Huynh, T., Tay, Y., Ang, Y.-S., Tam, W.-L., Thomson, A. M., Lim, B., & Rigoutsos, I. (2006) · Cell · doi:10.1016/j.cell.2006.07.031 · Cited by 1,739 · see citing works
Ventura, A., Young, A. G., Winslow, M. M., Lintault, L., Meissner, A., Erkeland, S. J., Newman, J. J., Bronson, R. T., Crowley, D. G., Stone, J. R., et al. (2008) · Cell · doi:10.1016/j.cell.2008.02.019 · Cited by 1,592 · see citing works
Widespread microRNA repression by Myc contributes to tumorigenesis
Chang, T.-C., Yu, D., Lee, Y., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas‐Tikhonenko, A., & Mendell, J. T. (2007) · Nature Genetics · doi:10.1038/ng.2007.30 · Cited by 1,326 · see citing works
The miR-34 family in cancer and apoptosis
Hermeking, H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.56 · Cited by 1,236 · see citing works
Croce, C. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmra072367 · Cited by 1,055 · see citing works
Self-citationInternational Myeloma Working Group molecular classification of multiple myeloma: spotlight review
Fonseca, R., Bergsagel, P. L., Drach, J. W., Shaughnessy, J. D., Gutierrez, N. C., Stewart, A. K., Morgan, G. J., Ness, B. V., Chesi, M., Minvielle, S., et al. (2009) · Leukemia · doi:10.1038/leu.2009.174 · Cited by 886 · see citing works
Multiple myeloma: evolving genetic events and host interactions
Kuehl, W. M., & Bergsagel, P. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc746 · Cited by 818 · see citing works
Shangary, S., Qin, D., McEachern, D., Liu, M., Miller, R. S., Qiu, S., Nikolovska-Coleska, Z., Ding, K., Wang, G., Chen, J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708917105 · Cited by 660 · see citing works
miR-29 miRNAs activate p53 by targeting p85α and CDC42
Park, S. Y., Lee, J. H., Ha, M., Nam, J., & Kim, V. N. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1533 · Cited by 608 · see citing works
A monoclonal gammopathy precedes multiple myeloma in most patients
Weiss, B. M., Abadie, J. M., Verma, P. S., Howard, R. S., & Kuehl, W. M. (2009) · Blood · doi:10.1182/blood-2008-12-195008 · Cited by 568 · see citing works
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
Pichiorri, F., Suh, S.-S., Ladetto, M., Kuehl, M., Palumbo, T., Drandi, D., Taccioli, C., Zanesi, N., Alder, H., Hagan, J. P., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806202105 · Cited by 563 · see citing works
Self-citationmicroRNAs join the p53 network — another piece in the tumour-suppression puzzle
He, L., He, X., Lowe, S. W., & Hannon, G. J. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2232 · Cited by 546 · see citing works
p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest
Braun, C. J., Zhang, X., Savelyeva, I., Wolff, S., Moll, U. M., Schepeler, T., Orntoft, T. F., Andersen, C. L., & Dobbelstein, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1569 · Cited by 467 · see citing works
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354 · see citing works
Coordinated Regulation of Cell Cycle Transcripts by p53-Inducible microRNAs, miR-192 and miR-215
Georges, S. A., Biery, M. C., Kim, S., Schelter, J. M., Guo, J., Chang, A. N., Jackson, A. L., Carleton, M. O., Linsley, P. S., Cleary, M. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1846 · Cited by 348 · see citing works
p53 — a Jack of all trades but master of none
Junttila, M. R., & Evan, G. I. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2728 · Cited by 344 · see citing works
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Roccaro, A. M., Sacco, A., Thompson, B. D., Leleu, X. P., Azab, A. K., Azab, F., Runnels, J. M., Jia, X., Ngo, H. T., Melhem, M. R., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198408 · Cited by 313 · see citing works
Danovi, D., Meulmeester, E., Pasini, D., Migliorini, D., Capra, M., Frenk, R., de Graaf, P., Francoz, S., Gasparini, P., Gobbi, A., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5835-5843.2004 · Cited by 310 · see citing works
Galm, O., Yoshikawa, H., Esteller, M., Osieka, R., & Herman, J. G. (2003) · Blood · doi:10.1182/blood-2002-06-1735 · Cited by 308 · see citing works
Lionetti, M., Biasiolo, M., Agnelli, L., Todoerti, K., Mosca, L., Fabris, S., Sales, G., Deliliers, G. L., Bicciato, S., Lombardi, L., et al. (2009) · Blood · doi:10.1182/blood-2009-08-237495 · Cited by 238 · see citing works
Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor
Girnita, L., Girnita, A., & Larsson, O. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1431613100 · Cited by 223 · see citing works
Gutierrez, N. C., Sarasquete, M. E., Misiewicz-Krzemińska, I., Delgado, M., Rivas, J. D. L., Ticona, F. V., Fermiñán, E., Martín‐Jiménez, P., Chillón, C., Risueño, A., et al. (2010) · Leukemia · doi:10.1038/leu.2009.274 · Cited by 213 · see citing works
Genetic events in the pathogenesis of multiple myeloma
Chng, W. J., Glebov, O. K., Bergsagel, P. L., & Kuehl, W. M. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.004 · Cited by 189 · see citing works
Song, B., Wang, Y., Kudo, K., Gavin, E. J., Xi, Y., & Ju, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1422 · Cited by 146 · see citing works
Insulin-like growth factor I induces migration and invasion of human multiple myeloma cells
Qiang, Y., Yao, L., Tosato, G., & Rudikoff, S. (2003) · Blood · doi:10.1182/blood-2003-06-2066 · Cited by 143 · see citing works
Hino, K., Tsuchiya, K., Fukao, T., Kiga, K., Okamoto, R., Kanai∥, T., & Watanabe, M. (2008) · RNA · doi:10.1261/rna.810208 · Cited by 139 · see citing works
MicroRNA 125a and its regulation of the p53 tumor suppressor gene
Zhang, Y.-J., Gao, J.-S., Tang, X., Tucker, L., Quesenberry, P., Rigoutsos, I., & Ramratnam, B. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.10.002 · Cited by 112 · see citing works
MDM2 Protein Overexpression Promotes Proliferation and Survival of Multiple Myeloma Cells
Teoh, G. K. H., Urashima, M., Ogata, A., Chauhan, D., DeCaprio, J. A., Treon, S. P., Schlossman, R. L., & Anderson, K. C. (1997) · Blood · doi:10.1182/blood.v90.5.1982 · Cited by 97 · see citing works
Small-molecule inhibitors of MDM2 as new anticancer therapeutics
Dickens, M. P., Fitzgerald, R. P., & Fischer, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.003 · Cited by 86 · see citing works
Ooi, M. G. M., Hayden, P. J., Kotoula, V., McMillin, D. W., Charalambous, E., Daskalaki, E., Raje, N. S., Munshi, N. C., Chauhan, D., Hideshima, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1071 · Cited by 69 · see citing works
Over‐expression of the MDM2 gene is found in some cases of haematological malignancies
Quesnel, B., Preudhomme, C., Oscier, D. G., Lepelley, P., Hooghe, M. C., Facon, T. T. F., Zandecki, M., & Fenaux, P. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb05044.x · Cited by 64 · see citing works
Pharmacological activation of the p53 pathway in haematological malignancies
Saha, M. N., Micallef, J., Qiu, L., & Chang, H. (2009) · Journal of Clinical Pathology · doi:10.1136/jcp.2009.070961 · Cited by 51 · see citing works
Dissecting microregulation of a master regulatory network
Sinha, A. U., Kaimal, V., Chen, J., & Jegga, A. G. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-88 · Cited by 44 · see citing works
Tai, Y., Podar, K., Catley, L., et al. (2003) · Blood · Cited by 37 · see citing works
Lane, D. P. (2001) · Nature · doi:10.1038/35102132 · Cited by 29 · see citing works
Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival
Froment, P., Dupont, J., & Marine, J. (2008) · Cell Cycle · doi:10.4161/cc.7.19.6807 · Cited by 24 · see citing works
Stühmer, T., & Bargou, R. C. (2005) · Cell Cycle · doi:10.4161/cc.5.1.2281 · Cited by 17 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279 · see citing works
Lujambio, A., & Lowe, S. W. (2012) · Nature · doi:10.1038/nature10888 · Cited by 1,084 · see citing works
MicroRNAs in the p53 network: micromanagement of tumour suppression
Hermeking, H. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3318 · Cited by 518 · see citing works
MicroRNA controls of cellular senescence
Suh, N. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.10.209 · Cited by 78 · see citing works
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38 · see citing works
Herman, A. B., Anerillas, C., Harris, S. C., Munk, R., Martindale, J. L., Yang, X., Mazan-Mamczarz, K., Zhang, Y., Heckenbach, I. J., Scheibye-Knudsen, M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab538 · Cited by 31 · see citing works
- Authors
- Pichiorri, F., Suh, S.-S., Rocci, A., De Luca, L., Taccioli, C., Santhanam, R., Zhou, W., Benson, D. M., Hofmainster, C., Alder, H., Garofalo, M., Di Leva, G., Volinia, S., Lin, H.-J., Perrotti, D., Kuehl, M., Aqeilan, R. I., Palumbo, A., & Croce, C. M.
- Affiliations
- Hebrew University of Jerusalem (IL)
- University of Turin (IT)
- University College London (GB)
- The Ohio State University (US)
- University of Ferrara (IT)
- National Cancer Institute (US)
- Corresponding author
- Pichiorri, Flavia
- Croce, Carlo M.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-10
- Volume
- 18
- Issue
- 4
- Pages
- 367-381
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC3561766
- OpenAlex
- W2146483998
- Cited by
- 436
- References
- 44
- Citations by year
- 2025: 2 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 24 · 2020: 37 · 2019: 30 · 2018: 38 · 2017: 34 · 2016: 37 · 2015: 23 · 2014: 62 · 2013: 38 · 2012: 42
- FWCI
- 17.21
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Ohio State University
- Sidney Kimmel Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- multiple myeloma, p53, MDM2, microRNA-192, p53 downregulation, tumor suppressor, retracted article, data falsification, figure duplication, scientific misconduct investigations
- MeSH terms
- Animals, Cell Cycle, Cell Movement, Chromosomes, Human, Pair 11, Homeostasis, Humans, Insulin-Like Growth Factor I, Models, Biological, Multiple Myeloma, Mutagens, Neoplasm Invasiveness, Precancerous Conditions, Promoter Regions, Genetic, RNA, Messenger, Down-Regulation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Receptor, IGF Type 1, DNA Methylation, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
